All
Edit your video clips for Internet
September 1st 2004A large video clip can be difficult to send over the Internet, and can be difficult for viewers to download... Reducing the frame rate to one-third of the original led to a great reduction in file size, and it reduced the rate at which data had to be sent.
Physician says TNF-? antagonists very safe overall
September 1st 2004New York - While dermatologists need to be aware of legitimate safety issues when prescribing any of the TNF-? antagonists for the treatment of psoriasis, as a bottom line, adalimumab (Humira, Abbott Immunology), etanercept (Enbrel, Amgen/Wyeth), and infliximab (Remicade, Centocor) appear to be safer than some older psoriasis treatments, such as methotrexate and cyclosporine, says Mark Lebwohl, M.D., Sol and Clara Kest Professor and chairman, department of dermatology, Mount Sinai School of Medicine, New York.
For optimal result, begin treating with biologic while tapering conventional systemic therapy
September 1st 2004Dallas - For psoriasis patients just starting treatment, as well as those who've had poor results from conventional systemic therapies, biologics are a good first-line treatment option. But what about those who've had good results with methotrexate and cyclosporine and are forced to consider alternatives?
New oral psoriasis agents show promise
September 1st 2004New York - While acitretin remains a common oral treatment for psoriasis, oral tazarotene (Allergan), fumaric acid esters (FAEs), and oral pimecrolimus can cut side effects ranging from alopecia to liver and kidney damage, according to a recent study.
It's time to reclaim patients with severe psoriasis
September 1st 2004Research shows that less than half of patients with severe psoriasis in the United States receive aggressive treatment - systemic drugs, biologic drugs or phototherapy - for their disease. The total number of severely psoriatic patients has been estimated at 120,000 to 450,000 or more.
Botulinum toxin long-term safety study finds 'no news is good news'
September 1st 2004New York - Results of a retrospective review reinforce the long-term safety and tolerability of repeated treatments with botulinum toxin type A (Botox Cosmetic?, Allergan) for cosmetic reasons, said Alastair Carruthers, M.D., at the American Academy of Dermatology's Academy '04 here recently.
Novel agent, chemotherapy promising in melanoma tx
September 1st 2004New Orleans - BAY 43-9006, a novel signal transduction inhibitor, has very modest activity as a single agent in melanoma; however, it has promising activity in combination with chemotherapy, investigators said at the annual meeting of the American Society of Clinical Oncology (ASCO).
Biologics promise efficacy, convenience but few studied for indication in children
September 1st 2004Charleston, S.C. - Biologic agents for pediatric dermatology offer the promise of being safer and much easier to use than traditional drugs, according to Elaine C. Siegfried, M.D., associate clinical professor of pediatrics and dermatology at St. Louis University School of Medicine, Mo.
Legislation to improve patient safety; create “safe environment”
September 1st 2004Dermatologists and other healthcare providers are soon expected to have a formal mechanism for reporting medical errors and near misses without having to worry that the information will be used against them in a lawsuit.
Researchers make inroads in combination immunotherapy for melanoma
September 1st 2004New York - Melanoma-derived peptide vaccines are currently an exciting area of melanoma immuno-therapy research, according to Douglas J. Schwartzentruber, M.D., medical director and director of the Center for Cancer Care at Goshen Health System, Goshen, Ind., speaking at the Society of Surgical Oncology annual meeting.
Novel patch delivers local anesthesia with convenience, quickness, safety
September 1st 2004New York-An easy-to-use, self-warming patch containing lidocaine and tetracaine provides effective local anesthesia for minor dermatological procedures in adult patients, said Brian Berman, M.D., Ph.D, at the American Academy of Dermatology's Academy '04 meeting here.
Melasma treatments - from frustration to fruition?
September 1st 2004Eilat, Israel - For the last 50 years, hydroquinone has been the reference of treatment in hyperpigmentations, and more recently, combination formulas, peelings and adjuvant therapies including sunscreens containing the drug, show promise. However, topical agents have yet to prove a constant and uncontested efficiency, said Daphne Thioly-Bensoussan M.D., during the 28th Annual Meeting of the Israeli Conference of Dermatology and Venerology.